Journal of SAFOMS

Register      Login

VOLUME 1 , ISSUE 2 ( July-December, 2013 ) > List of Articles


A Study of Coronary Heart Disease in Postmenopausal Women and Identification of Major Modifiable Determinant Risks for its Prevention

P Pradhan, AV Upadhya

Citation Information : Pradhan P, Upadhya A. A Study of Coronary Heart Disease in Postmenopausal Women and Identification of Major Modifiable Determinant Risks for its Prevention. J South Asian Feder Menopause Soc 2013; 1 (2):56-62.

DOI: 10.5005/jp-journals-10032-1013

Published Online: 01-12-2013

Copyright Statement:  Copyright © 2013; The Author(s).


PDF Share
  1. Gender difference in the treatment and outcome of acute myocardial infarction: results from myocardial infarction Triage and intervention Registry. Arch Intern Med 1992;1542:972-976.
  2. Womens cardiovascular health: prospectives from South East Asia. Nat Rev Cardol 2012;24(9):464-477.
  3. Current diagnostic concepts to detect Coronary artery disease in women. European Heart Journal 2008;29:707-717.
  4. Mortality for women after acute myocardial infarction: Milis study group. Am J Cardid 1989;64:256.
  5. The changing in hospital mortality of women undergoing percutaneous tranluminal coronary angioplasty. JAMA 1993;269:2091-2095.
  6. Coronary heart disease: an older women's major health risk. BMJ 1998;13:124-152.
  7. Changing clinical characteristics of coronary surgery patients. Difference between men and women. Circulation 1993;88:79-86.
  8. Trends and disparities in coronary heart disease, stroke and other cardiovascular disease in the United States: findings of the national conference on cardiovascular disease prevention. Circulation 2000;102:3137.
  9. The primary prevention of myocardial infarction. N Eng J Med 1992;326:1406-1416.
  10. Secondary prevention in coronary heart disease: baseline survey of provision in general practice. BMJ 1998;316:1430-1434.
  11. A Bristish Cardiac Society Survey of the potential for the secondary prevention of coronary disease: ASPIRE (Action on secondary prevention through intervention to reduce events). Heart 1996;75:334-342.
  12. Noncardiovascular disease outcome during 6 to 8 years of hormone therapy. Heart and Estrogen/Progestin replacement study follow-up (HERSII) JAMA 2002;288:58.
  13. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465.
  14. Risk and benefit of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321-333.
  15. Reducing the health consequences of smoking. 25 years of progress: a report of the surgeon general. Washington DC. Government Printing Office DHHS Publication No. (CDC) 8411;1989.
  16. Hormone replacement therapy and cardiovascular disease: a start for healthcare professionals from the American heart association. Circulation 2001;104:499.
  17. Relative and absolute excess risk of CHD among women who smoke cigarettes. N Eng J Med 1987;314:103-109
  18. Smoking cessation in relation to total mortality rates in women. Ann Intern Med 1993;119:992-1000.
  19. The relationship of smoking cessation to coronary heart disease and lung cancer in the multiple risk factor interventional trail (MRFIT). Am J Public Health 1990;80:954-958.
  20. Blood pressure, stroke and coronary heart disease part I. Prolong differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990;335:765-774.
  21. Blood pressure, stroke and coronary heart disease part 2 short term reduction in blood pressure: overview of randomized drugs trial in their epidermiologic context. Lancet 1990;335:827-838.
  22. Perspective on systolic hypertension: The framingham Study. Circulation 1980;61:1179-1182.
  23. SHEP Co-operative Research Group. JAMA 1991;265:3255-3264.
  24. Range of serum cholesterol values in the population developing coronary artery disease. Am J Cardiol 1995;76:69-77.
  25. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol level. N Eng J Med 1996;335:1001-1008.
  26. Cost-effectiveness of lowering cholesterol concentration with statins in patients with or without preexisting coronary heart disease life table method applied to health authority population. BMJ 1996;312:1643-1648.
  27. The Tromsq Heart study; high density lipoproteins and coronary heart disease: a prospective case-control study. Lancet 1977;1:965-968.
  28. High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women. The followup study of lipid research clinics prevalence study. Am J Epidemiol 1990;131:32-47.
  29. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979;241:2035-2038.
  30. Glycemic effects of postmenopausal hormone therapy: The heart and estrogen/ progestin replacement. A randomized, Double-blind placebocontrolled trial. Ann Intern Med 2003;138:1-9.
  31. Effects of oestrogen and progestin on the incidence of diabetes in post menopause women: results from the women's health initiative hormone Trial Diabetologia 2004;47:1175.
  32. A prospective study of obesity and risk of coronary heart disease in women. N Eng JM Ed 1990;322:882-889.
  33. Obesity as an independent risk factor for cardiovascular disease. A 26 years follow-up of participants in the Framingham heart study. Circulation 1983;67:968-977.
  34. Leisure time physical activity and the risk of nonfatal myocardial infarction in postmenopausal women. Arch Intern Med 1995;27:2302-2308.
  35. Socioeconomic factors and physical activity in relation to cardiovascular disease and death: a 12 years follow-up of participants in a population study of women in Gothenburg. Sweden Br Heart Jr 1985;55:295-301.
  36. Physical activity and mortality in postmenopausal women. JAMA 1997;277:1287-1292.
  37. Some characteristics of the incidence of cardiovascular disease and death: framingham study: 16 years follow-up. Section 26 of the framingharm study. Washington DC: Government Printing Office; 1970.
  38. The prospective study of moderate alcohol consumption and risk of coronary disease and stroke in women. N Eng J Med 1988;319:267-273.
  39. Aspirin for the primary prevention of cardiovascular events in women and men. A sex-specific meta-analysis of randomized control trials. JAMA 2006;295:3061.
  40. A randomized trial of low dose aspirin in the primary prevention of cardiovascular disease in women. N Eng J Med 2005;352:1293.
  41. AHA guidelines for primary prevention of cardiovascular disease or stroke: 2002 update: Circulation 2002;106:388.
  42. Braunwald's heart disease: cardiac protection with aspirin. Elsevier Saunder Publisher. 8th ed. 2008. 1133 p.
  43. Collaborative metaanalysis of randomised trial of antiplatelet therapy for prevention of death, MI and stroke in high-risk patients. BMJ 2002;324:71.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.